Thursday, June 4, 2020 Daily Archives

How to avoid a post-COVID manufacturing crisis

by

How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors. It is important to start planning for post-COVID-19 recovery even as the pandemic continues to impact pharmaceutical manufacturing operations, an expert panel told Food and Drug Law Institute members during a 19 May webinar. Manufacturers should set priorities in advance so they can attack the most important backlogged activities first. They also should approach recovery with the right mindset: the need to act…

June 4, 2020

COVID-19 round-up: Vaccine capacity M&A, deals and task orders

by

Emergent has received $628 million to support vaccine production; Novavax buys Czech Republic-based Praha Vaccines; Vaxart contracts Kindred Biosciences. Just another week in the fight against COVID-19. Emergent Biosolutions is working on several projects to support the development of COVID-19 vaccines but has been buoyed by a US government task order of $628 million to support rapid domestic production through 2021. The task order forms part of a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department…

June 4, 2020

COVID-19 vaccine: A $14bn opportunity for bioprocess vendors

by

The big four bioprocess vendors – Thermo Fisher, Danaher, MilliporeSigma, and Sartorius – are set to benefit from the commercial success of COVID-19 vaccines, according to Evercore ISI. There are a host of vaccine candidates targeting the novel coronavirus (SARS-CoV-2) moving into and through the clinic, and while there is no guarantee of success a breakthrough product will be a lucrative market opportunity. Specifically, a commercialized product could be worth upwards of $100 billion (€89 billion), according to the team…

June 4, 2020